---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021715"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:55:52.256724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q3 revenue +22% to $26.3M; net income from continuing ops positive; THP discontinued

## Summary
- Q3 net revenue $26.3M (+22% YoY); net income from continuing ops $0.8M vs loss $0.2M; Adj. EBITDA $4.9M (+$2.3M).
- Soft tissue repair revenue +24% driven by CellerateRX and BIASURGE; gross margin improved to 93% from 91%.
- Operations of Tissue Health Plus (THP) ceased in Q3; $26.5M noncash impairment charge; THP classified as discontinued ops.
- Net loss from discontinued ops $31.2M in Q3; overall net loss $30.4M vs $2.9M loss YoY from continuing and disc ops.
- Seth Yon appointed CEO effective Sept 15, 2025; Ron Nixon remains Executive Chairman.

## SEC filing metadata
- accession: 0001493152-25-021715
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315225021715/0001493152-25-021715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315225021715/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021715
- JSON: https://secwatch.observer/filing/0001493152-25-021715.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.